Product Images Finasteride

This figure shows the percentage of patients who had surgery for benign prostatic hyperplasia (BPH) including transurethral resection of the prostate (TURP) over a 48-month observation period. The data compares the use of finasteride versus placebo. The x-axis of the graph represents the observation time in months and the y-axis represents the percentage of patients who underwent surgery for BPH. The line for finasteride is consistently below that of the placebo, indicating a lower percentage of patients who underwent surgery in the finasteride group. The graph also includes information on the number of events and patients at risk for each group.*

The figure 3 shows the percentage of patients developed acute urinary retention due to spontaneous and precipitated causes. However, no explanation or context is available to interpret the data accurately.*

This is a graph showing the mean percent change from baseline in prostate volume over the course of a long-term efficacy and safety study. The study tracked the progress of two groups of patients, one receiving a placebo and the other receiving finasteride. The data shows that over the course of three years, patients receiving finasteride experienced a consistently greater reduction in prostate volume compared to those receiving a placebo. These results suggest that finasteride may be an effective treatment for patients with benign prostatic hyperplasia (BPH).*

This is a list of packages of Finasteride Tablets, USP 5mg, with various quantities and lot and batch numbers. The drug is RX only and these packages are distributed by Rising Health, LLC. The CAUTION message is present, which states that federal law prohibits dispensing without prescription and to keep out of reach of children. The storage temperature of the drug is also indicated as 20-25C. The packages are produced and labeled by Enovachem.*